Septerna Inc (SEPN) Stock Price, Quote & News

Company Profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 338 3533

Website: septerna.com

Address:

250 East Grand Avenue, South San Francisco, United States

ItsTheEagle Jul. 16 at 7:34 PM

$SEPN high risk, high potential reward. Took a small position here

0 · Reply

MadStockAlerts1 Jul. 8 at 1:16 PM

$SEPN watch it 🔥

0 · Reply

MadStockAlerts1 Jul. 8 at 5:26 AM

$SEPN 🔥 isn't making noise, it's making progress. Moving averages are stacked in the right order and the uptrend hasn't broken stride once. That's the kind of quiet, deliberate action that we love to see 🦾

0 · Reply

topstockalerts Jul. 8 at 1:32 AM

$SEPN the action here feels increasingly deliberate.

0 · Reply

twitsblast Jul. 7 at 2:44 PM

$SEPN 🚨 $CHAI names new CFO, formerly with $RGNT, $GLMD, and $PLRZ. 💥

0 · Reply

FionaTradesStocks Jun. 29 at 1:33 PM

$SEPN Is this a joke?

0 · Reply

WallStWireAds Jun. 22 at 2:22 PM

$ENTX With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For >> https://www.benzinga.com/content/60014792/positive-fda-feedback-phase-3-entera-bio-just-got-answer-market-was-waiting $LLY $NVOS $SEPN

0 · Reply

WallStWireAds Jun. 22 at 12:31 PM

$ENTX Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis https://www.globenewswire.com/news-release/2026/06/22/3315282/0/en/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613-the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosi.html $LLY $SEPN $NVOS

0 · Reply

notreload_ai Jun. 11 at 3:13 PM

Analysts initiate coverage with Buy ratings on $SNSE, $SEPN, $KZIA, $NGEN, and $STRO. https://notreload.xyz/xy/5-hot-biotech-stocks-with-fresh-buy-ratings/

0 · Reply

EMPIR3_37 May. 14 at 8:32 PM

$SEPN Just a matter of time until people find out about this. PTs in the 40s. See ya there

0 · Reply

Septerna price target raised to $43 from $35 at Truist

2026-07-01T10:50:37.000Z - 17 days ago

Septerna price target lowered to $45 from $52 at Guggenheim

EVMN

Jun 26, 2026, 5:00 PM EDT - 21 days ago

Septerna Transcript: AGM 2026

2026-06-11T10:23:07.000Z - 5 weeks ago

Septerna initiated with a Buy at Guggenheim

2026-06-08T12:16:55.000Z - 5 weeks ago

Septerna to present preclinical characterization of SEP-479

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

2026-06-08T10:35:53.000Z - 5 weeks ago

Septerna price target raised to $53 from $47 at Raymond James

2026-05-26T14:33:56.000Z - 7 weeks ago

3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026

ANGO KRNT

May 12, 2026, 8:00 PM EDT - 2 months ago

Septerna Transcript: Bank of America Global Healthcare Conference 2026

2026-05-11T21:33:42.000Z - 2 months ago

Septerna reports Q1 EPS (19c), consensus (27c)

May 11, 2026, 4:01 PM EDT - 2 months ago

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 2 months ago

Septerna Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Septerna Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 2 months ago

Septerna to Present at Bank of America Securities Health Care Conference

2026-04-30T20:39:44.000Z - 2 months ago

Septerna initiated with a Buy at Stifel

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Septerna Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Septerna Proxy statement: Proxy filing

2026-04-13T12:16:55.000Z - 3 months ago

Septerna doses first patients in SEP-479 trial

Apr 13, 2026, 8:00 AM EDT - 3 months ago

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

2026-03-24T11:27:17.000Z - 4 months ago

Septerna price target raised to $38 from $34 at JPMorgan

2026-03-11T11:51:58.000Z - 4 months ago

Septerna price target raised to $35 from $34 at Truist

2026-03-10T20:35:29.000Z - 4 months ago

Septerna files automatic mixed securities shelf

2026-03-09T20:40:12.000Z - 4 months ago

Septerna reports Q4 EPS (24c), consensus (22c)

Mar 9, 2026, 4:05 PM EDT - 4 months ago

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 9:30 AM EDT - 4 months ago

Septerna Annual report: Q4 2025

Mar 9, 2026, 9:30 AM EDT - 4 months ago

Septerna Earnings release: Q4 2025

Mar 3, 2026, 3:10 PM EST - 4 months ago

Septerna Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 6:00 PM EST - 4 months ago

Septerna Slides: Corporate presentation

2026-03-02T15:10:09.000Z - 4 months ago

Septerna price target raised to $40 from $35 at H.C. Wainwright

Mar 2, 2026, 8:00 AM EST - 4 months ago

Septerna Transcript: Study result

Mar 2, 2026, 8:00 AM EST - 4 months ago

Septerna Press release: Study result

Mar 2, 2026, 8:00 AM EST - 4 months ago

Septerna Slides: Study result

2026-03-01T16:30:07.000Z - 4 months ago

Septerna announces results from Phase 1 trial of SEP-631

Mar 1, 2026, 9:45 AM EST - 4 months ago

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Feb 24, 2026, 8:00 AM EST - 5 months ago

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Feb 10, 2026, 4:05 PM EST - 5 months ago

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 10, 2026, 8:00 AM EST - 5 months ago

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

2026-01-20T11:20:10.000Z - 6 months ago

Septerna price target raised to $35 from $30 at H.C. Wainwright

Jan 13, 2026, 6:45 PM EST - 6 months ago

Septerna Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 7:00 AM EST - 6 months ago

Septerna Slides: Corporate presentation

2026-01-08T21:16:29.000Z - 6 months ago

Septerna appoints Mark Wilson as chief legal officer

NKTR

Jan 8, 2026, 4:05 PM EST - 6 months ago

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

2025-12-23T12:35:16.000Z - 7 months ago

Septerna initiated with a Buy at JonesResearch

Dec 17, 2025, 8:00 AM EST - 7 months ago

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 10:25 AM EST - 8 months ago

Septerna Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 8:00 AM EST - 8 months ago

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 4:00 PM EST - 8 months ago

Septerna Transcript: TD Cowen Immunology and Inflammation Summit

Nov 10, 2025, 4:00 PM EST - 8 months ago

Septerna Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 8 months ago

Septerna Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 8 months ago

Septerna Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 8:00 AM EST - 9 months ago

Septerna to Participate in Upcoming Investor Conferences

Sep 29, 2025, 4:01 PM EDT - 10 months ago

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Sep 5, 2025, 8:45 AM EDT - 11 months ago

Septerna Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 11:30 AM EDT - 11 months ago

Septerna Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Aug 11, 2025, 4:01 PM EDT - 1 year ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Septerna Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Septerna Earnings release: Q2 2025

Jun 5, 2025, 3:45 PM EDT - 1 year ago

Septerna Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Septerna to Present at Jefferies Global Healthcare Conference

May 15, 2025, 4:01 PM EDT - 1 year ago

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

May 14, 2025, 6:00 PM EDT - 1 year ago

Septerna Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Septerna Quarterly report: Q1 2025

May 14, 2025, 7:31 AM EDT - 1 year ago

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

NVO

May 14, 2025, 7:04 AM EDT - 1 year ago

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

NVO

May 14, 2025, 6:59 AM EDT - 1 year ago

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Septerna Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Septerna Proxy statement: Proxy Filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Septerna Earnings release: Q4 2024

Feb 26, 2025, 8:00 AM EST - 1 year ago

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 4:15 PM EST - 1 year ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 8:00 AM EST - 1 year ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Jan 14, 2025, 6:45 PM EST - 1 year ago

Septerna Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Septerna Slides: FY 2025

Dec 18, 2024, 8:00 AM EST - 1 year ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 7:00 AM EST - 1 year ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 19, 2024, 6:00 PM EST - 1 year ago

Septerna Quarterly report: Q3 2024

Nov 19, 2024, 6:00 PM EST - 1 year ago

Septerna Earnings release: Q3 2024

Oct 30, 2024, 4:41 PM EDT - 1 year ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 25, 2024, 12:25 PM EDT - 1 year ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 24, 2024, 9:47 PM EDT - 1 year ago

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 8:11 AM EDT - 1 year ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

ItsTheEagle Jul. 16 at 7:34 PM

$SEPN high risk, high potential reward. Took a small position here

0 · Reply

MadStockAlerts1 Jul. 8 at 1:16 PM

$SEPN watch it 🔥

0 · Reply

MadStockAlerts1 Jul. 8 at 5:26 AM

0 · Reply

topstockalerts Jul. 8 at 1:32 AM

$SEPN the action here feels increasingly deliberate.

0 · Reply

twitsblast Jul. 7 at 2:44 PM

$SEPN 🚨 $CHAI names new CFO, formerly with $RGNT, $GLMD, and $PLRZ. 💥

0 · Reply

FionaTradesStocks Jun. 29 at 1:33 PM

$SEPN Is this a joke?

0 · Reply

WallStWireAds Jun. 22 at 2:22 PM

0 · Reply

WallStWireAds Jun. 22 at 12:31 PM

0 · Reply

notreload_ai Jun. 11 at 3:13 PM

Analysts initiate coverage with Buy ratings on $SNSE, $SEPN, $KZIA, $NGEN, and $STRO. https://notreload.xyz/xy/5-hot-biotech-stocks-with-fresh-buy-ratings/

0 · Reply

EMPIR3_37 May. 14 at 8:32 PM

$SEPN Just a matter of time until people find out about this. PTs in the 40s. See ya there

0 · Reply

chole1 Apr. 10 at 7:59 PM

$SEPN High volume sell-off.. hope the Q2 P1 start for the PTH1R is all good.

0 · Reply

SuperGreenToday Apr. 7 at 9:36 PM

$SEPN Share Price: $24.84 Contract Selected: Oct 16, 2026 $32.0 Calls Buy Zone: $6.27 – $7.75 Target Zone: $10.41 – $12.72 Potential Upside: 57% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LovePNW Mar. 11 at 7:50 PM

$SEPN https://www.marketbeat.com/instant-alerts/truist-financial-forecasts-strong-price-appreciation-for-septerna-nasdaqsepn-stock-2026-03-11/

0 · Reply

shavitmi Mar. 6 at 1:57 PM

$TNYA if $ALNY a $40 bilion company works with TNYA i think its a home run $SEPN

0 · Reply

shavitmi Mar. 6 at 11:06 AM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

0 · Reply

shavitmi Mar. 5 at 8:26 PM

$TNYA the deal with $ALNY remind me the deal $SEPN did with novo

1 · Reply

LovePNW Mar. 3 at 9:14 PM

$SEPN https://www.marketbeat.com/instant-alerts/wells-fargo-company-increases-septerna-nasdaqsepn-price-target-to-4800-2026-03-03/

0 · Reply

IN0V8 Mar. 3 at 8:55 PM

$SEPN Buy Wells Fargo raises target price to $48 from $28

0 · Reply

AlertsAndNews Mar. 1 at 11:32 PM

$SEPN Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy "SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing" Conference call here tomorrow morning as well. "Company to Host Conference Call and Webcast on Monday, March 2, 2026, at 8:00 a.m. ET"

0 · Reply

Market Cap	1.42B
Revenue (ttm)	45.95M
Net Income (ttm)	-48.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.38%
Debt to Equity Ratio	0.00

Volume	306,400
Avg Vol	434,996
Day's Range	N/A - N/A
Shares Out	45.08M
Stochastic %K	38%
Beta	2.29
Analysts	Strong Sell
Price Target	$45.00